# US 6,730,490 B2 · In vitro methods for screening for blood coagulation disorders using metal ions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,490 B2
- Document ID: US6730490B2
- Status: Granted
- Kind: B2
- Application number: 10/050,441
- Filed: 2002-01-16
- Published: 2002-08-22
- Granted: 2004-05-04
- Earliest claimed: 1998-03-19
- Assignees: Instrumentation Laboratory Company
- Inventors: Bert Steffen Rosén; Christina Maria Yvonne Hall
- Web page: https://patentgrep.com/patent/US6730490B2

## CPC

- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- C12Q 1/56: involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- Y10S 435/975: Kit
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

In vitro methods for qualitative screening and/or quantitative determination of the functional activity of components of the Protein C anticoagulant pathway of blood coagulation are described. The methods entail measuring the conversion rate of a substrate by an enzyme, the activity of which is related to the Protein C anticoagulant activity, in a blood sample of a human comprising coagulation factors and said substrate, after at least partial activation of coagulation through the intrinsic, extrinsic or common pathway and triggering coagulation by adding calcium ions; and comparing said conversion rate with the conversion rate of a normal human blood sample determined in the same way. The methods include the addition of additional metal ions to the sample to enhance activity, sensitivity and resolution. Kits and reagents for use in the methods are also provided.

## Claims

### Claim 1

An in vitro method for determining the functional activity of one and more components of the Protein C anticoagulant pathway of the blood coagulation system, comprising:
(a) providing a blood sample to be analyzed;
(b) activating the coagulation cascade by adding a procoagulant reagent to the blood sample to be analyzed;
(c) triggering coagulation by adding calcium ions to the blood sample;
(d) adding metal ions selected from the group consisting of Mg+2, Mn+2, Zn+2, Ni+2, Sr+2, Cu+2, or Cu+, ions at a concentration that increases the anticoagulant activity of one or more components of the Protein C anticoagulant pathway;
(e) incubating a reaction mixture comprising the components recited in steps (a)-(d);
(f) observing clotting time; and
(g) comparing the clotting time for the blood sample to be analyzed with the clotting time for a normal blood sample as determined by the method recited in steps (a)-(f), thereby allowing for determination of an activity of one or more components of the Protein C anticoagulant pathway.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the metal ion comprises Mg+2.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the metal ion comprises Mg2+ and the amount of the Mg2+ ions added in step (d) is about 20 μmol to about 10 mmol per liter of reaction mixture.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the metal ion comprises Mg2+ and the amount of the Mg2+ ions added in step (d) is about 100 μmol to about 2 mmol per liter of reaction mixture.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the metal ion comprises Mg2+ and the amount of the Mg2+ ions added in step (d) is about 200 μmol to about 1 mmol per liter of reaction mixture.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the amount of Mn+2, Zn+2, Ni+2, Sr+2, Cu+2, or Cu+ ions added in step (d) is about 1 μmol to about 2 mmol per liter of reaction mixture.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the amount of Mn+2, Zn+2, Ni+2, Sr+2, Cu+2, or Cu+ ions added in step (d) is about 5 μmol to about 400 μmol per liter of reaction mixture.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the amount of Mn+2, Zn+2, Ni+2, Sr+2, Cu+2, or Cu+ ions added in step (d) is about 10 μmol to about 80 μmol per liter of reaction mixture.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the blood sample is selected from the group consisting of whole blood, blood plasma, and blood serum.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the activating, triggering, and adding steps occur separately.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the activating, triggering, and adding steps occur simultaneously.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the amount of calcium ions added in step (c) is about 0.5 mmol to about 20 mmol per liter of reaction mixture.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the amount of calcium ions added in step (c) is about 1 mmol to about 10 mmol per liter of reaction mixture.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the activating the coagulation cascade step occurs via the intrinsic pathway and the procoagulant reagent comprises at least one phospholipid and at least one contact activator.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the activating the coagulation cascade step occurs via the intrinsic pathway and the procoagulant reagent comprises at least one phospholipid and at least one intrinsic pathway factor selected from the group consisting of Factor IXa, Factor XIIa, and Factor XIa.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the activating the coagulation cascade step occurs via the intrinsic pathway and the procoagulant reagent comprises at least one phospholipid, at least one contact activator and at least one intrinsic pathway factor selected from the group consisting of Factor IXa, Factor XIIa, and Factor XIa.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the at least one contact activator is selected from the group consisting of collagen acid, collagen, collagen-related substances, and silica.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the at least one contact activator is a silica selected from the group consisting of micronized silica, colloidal silica, and kaolin.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the activating the coagulation cascade step occurs via the extrinsic pathway and the procoagulant reagent comprises a material selected from the group consisting of native human tissue factor, recombinant human tissue factor, non-human native tissue factor, non-human recombinant tissue factor, native human Factor VII/VIIa, recombinant human Factor VII/VIIa, native non-human Factor VII/VIIa, and recombinant non-human Factor VII/VIIa.

### Claim 20 (depends on 14, 15, 16)

The method as in any one of claims 14-16, wherein the at least one phospholipid is selected from the group consisting of synthetic phospholipids, purified phospholipids, and crude extracts of phospholipids derived from biological sources.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the at least one phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylserine, and sphingomyelin.

### Claim 22 (depends on 1)

The method according to claim 1, wherein the activating the coagulation cascade step occurs via the common pathway and the procoagulation reagent comprises a material selected from the group consisting of exogenous Factor Xa, exogenous Factor X and an exogenous activator for Factor X, and an exogenous activator for endogenous Factor X.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the exogenous activator for Factor X comprises snake venom enzyme.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the exogenous activator for Factor X comprises Russelli Viperii snake venom enzyme.

### Claim 25 (depends on 1)

The method according to claim 1, further comprising the step of adding at least one component selected from the group consisting of Protein C, activated Protein C, Protein S, Factor V, Factor Va, a plasma deficient of the Protein C anticoagulant pathway component to be analyzed, and a plasma deficient of all components of the Protein C anticoagulant pathway.

### Claim 26 (depends on 1)

The method according to claim 1, wherein a fibrin polymerization inhibitor is added to the blood sample to be analyzed.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the fibrin polymerization inhibitor comprises Gly-Pro-Arg-Pro.

### Claim 28 (depends on 1)

The method according to claim 1, wherein the procoagulant reagent comprises a material selected from the group consisting of Factor VIII, Factor VIIIa, Factor IX, Factor X, and prothrombin.

### Claim 29 (depends on 1)

The method according to claim 1, the method further comprising the step of providing activated Protein C by adding exogenous activated Protein C to the blood sample to be analyzed.

### Claim 30 (depends on 1)

The method according to claim 1, the method further comprising the step of providing activated Protein C by adding an activator of Protein C to the blood sample to be analyzed.

### Claim 31 (depends on 1)

The method according to claim 1, the method further comprising the step of providing activated Protein C by adding exogenous Protein C together with an activator of Protein C to the blood sample to be analyzed.

### Claim 32 (depends on 29, 30, 31)

The method as in any one of claims 29-31, wherein the adding metal ions step occurs simultaneously with the providing activated Protein C step.

### Claim 33 (depends on 29, 30, 31)

The method as in any one of claims 29-31, wherein the providing activated Protein C step occurs simultaneously with the activating the coagulation cascade step.

### Claim 34 (depends on 29, 30, 31)

The method as in any one of claims 29-31, wherein the providing activated Protein C step precedes the activating the coagulation cascade step.

### Claim 35 (depends on 29, 30, 31)

The method as in any one of claims 29-31, wherein the Protein C activator comprises at least one substance selected from the group consisting of Protein C activating snake venom enzyme and thrombin.

### Claim 36 (depends on 29, 30, 31)

The method as in any of claims 29-31, wherein the Protein C activator comprises thrombomodulin.

### Claim 37 (depends on 29, 30, 31)

The method as in any one of claims 29-31, wherein the Protein C activator comprises recombinant Protein C activator.

### Claim 38 (depends on 35)

The method according to claim 35, wherein the Protein C activating snake venom enzyme is obtained from the Agkistrodon family.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the snake venom enzyme is obtained from Agkistrodon contortrix contortrix.

### Claim 40 (depends on 38)

The method according to claim 38, wherein the snake venom enzyme comprises crude snake venom enzyme.

### Claim 41 (depends on 38)

The method according to claim 38, wherein the snake venom enzyme comprises purified snake venom enzyme.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the amount of purified snake venom enzyme is about 1×10−3 U to about 1 U per milliliter of reaction mixture.

### Claim 43 (depends on 41)

The method according to claim 41, wherein the amount of purified snake venom enzyme added is about 2×10−3 U to about 0.3 U per milliliter of reaction mixture.
